MedTrace Logo

Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

NCT04597164 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-11-29

No results posted yet for this study

Summary

This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.

Conditions

  • Hepatitis B, Chronic
  • Acute-On-Chronic Liver Failure

Interventions

OTHER

Artificial liver support system

Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Liang Peng, Doctor · Third Affiliated Hospital, Sun Yat-Sen University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04597164 on ClinicalTrials.gov